Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Polyomavirus and related diseases, and Amyotrophic Lateral Sclerosis Research.
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome
Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management
Smouldering‐Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions
Rituximab treatment in <scp>pediatric‐onset</scp> multiple sclerosis
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
A multicentre validation study of the diagnostic value of plasma neurofilament light
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Inflammation-related plasma and CSF biomarkers for multiple sclerosis
Blood neurofilament light levels segregate treatment effects in multiple sclerosis
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
Aggressive multiple sclerosis (1): Towards a definition of the phenotype
Aggressive multiple sclerosis (2): Treatment
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
Rituximab in paediatric onset multiple sclerosis: a case series
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience